Apolipoprotein ϵ4 allele and disease progression in patients with late-onset Alzheimer's disease

https://doi.org/10.1016/0304-3940(94)11107-TGet rights and content

Abstract

A random sample of 60 late-onset Alzheimer's disease (AD) cases from a population-based study were apolipoprotein E (apoE) genotyped and clinically examined with a 3-year interval. The ϵ4 allele carriers had a significantly lower age of disease onset compared to non-E4 carriers. However, no significant differences were observed between ϵ4 allele carriers and non-carriers for Mini-Mental State Examination (MMSE) test scores at the first examination, in spite of a longer disease duration in the ϵ4 allele carriers. After 3 years, MMSE test scores were still not significantly different between ϵ4 carriers and non-carriers but more than twice as many non-carriers had died. All other clinical features were similar between ϵ4 allele carriers and non-carriers. This study indicates that the ϵ4 allele is associated with a better prognosis of the disease in late-onset AD but that there are probably factors other than the ϵ4 allele that are important for the AD phenotype.

References (13)

There are more references available in the full text version of this article.

Cited by (88)

  • Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease

    2017, Alzheimer's and Dementia
    Citation Excerpt :

    Various lines of evidence indicate the impact of genetic biomarkers on the progression of cognitive decline in AD-related dementia [8], whereas it has not yet been established whether RCD occurs more commonly in early onset familial AD [9]. The association between the APOE ε4 allele and cognitive decline in patients with AD remains controversial [10–30]. In addition, the presence of the K and A variant alleles of the butyrylcholinesterase gene have been associated with slower cognitive decline in patients with severe AD [31,32].

  • Genetics of Alzheimer Disease

    2013, Emery and Rimoin's Principles and Practice of Medical Genetics
  • Genetic heterogeneity of Alzheimer's disease: Complexity and advances

    2007, Psychoneuroendocrinology
    Citation Excerpt :

    On the other hand, those with the ε4 allele were thought to have a lower mortality rate (van Duijn et al., 1995). Several studies further suggest that disease duration is longer in patients with an ε4 allele (Basun et al., 1995). These different observations have led some authors to hypothesize that the association between the ε4 allele and disease may be due simply to the longer disease duration in the cases, which thus induces an artificial increase in allele frequency in case–control studies.

View all citing articles on Scopus
View full text